HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of recalcitrant warts with intralesional measles, mumps, and rubella vaccine: a promising approach.

AbstractBACKGROUND:
Recalcitrant warts represent a frustrating challenge for both patients and physicians. Although many destructive and immunotherapeutic modalities are available for the treatment of warts, an ideal, universally effective approach has not been explored to date. Recently, intralesional antigen immunotherapy has shown promising efficacy in the treatment of warts. The aim of the study was to evaluate the efficacy and safety of intralesional measles, mumps, and rubella (MMR) vaccine in the treatment of recalcitrant warts.
METHODS:
The study included 70 adult patients with multiple recalcitrant extragenital warts of different sizes and durations, with or without distant warts. They were directly injected, without a pre-sensitization skin test, with 0.3 intralesional MMR vaccine into the largest wart at 2-week intervals until complete clearance or for a maximum of five treatments. Follow-up was made every month for six months to detect any recurrence.
RESULTS:
Sixty-five patients, 35 men and 30 women, completed the study, and five patients discontinued for various reasons. Complete clearance of the lesions was observed in 41 patients (63%), partial response in 15 patients (23%), and no response in nine patients (14%). Complete response was demonstrated in 74.5% of those presenting with distant warts. Side effects were mild and insignificant in the form of pain during injection, itching, erythema, and edema at the site of injection and flu-like symptoms. Recurrence was detected in two patients only.
CONCLUSIONS:
Intralesional immunotherapy by MMR vaccine is a promising, effective, and safe treatment modality for recalcitrant warts.
AuthorsAhmad Nofal, Eman Nofal, Ayman Yosef, Hager Nofal
JournalInternational journal of dermatology (Int J Dermatol) Vol. 54 Issue 6 Pg. 667-71 (Jun 2015) ISSN: 1365-4632 [Electronic] England
PMID25070525 (Publication Type: Clinical Trial, Journal Article)
Copyright© 2014 The International Society of Dermatology.
Chemical References
  • Measles-Mumps-Rubella Vaccine
Topics
  • Adolescent
  • Adult
  • Female
  • Humans
  • Immunotherapy
  • Injections, Intralesional
  • Male
  • Measles-Mumps-Rubella Vaccine (administration & dosage)
  • Middle Aged
  • Recurrence
  • Warts (therapy)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: